Vaccines,
Journal Year:
2024,
Volume and Issue:
12(12), P. 1401 - 1401
Published: Dec. 12, 2024
The
research
conducted
in
this
preclinical
study
assesses
QazCovid-live,
a
live
attenuated
COVID-19
vaccine
created
Kazakhstan,
by
conducting
evaluations
of
safety,
immunogenicity,
and
allergenicity
various
animal
models,
including
mice,
rats,
hamsters,
guinea
pigs.
vaccine,
developed
attenuating
SARS-CoV-2
via
numerous
Vero
cell
passages,
had
no
significant
adverse
effects
acute
subacute
toxicity
assessments,
even
at
elevated
dosages.
Allergenicity
testing
indicated
the
absence
both
immediate
delayed
hypersensitivity
reactions.
Immunogenicity
revealed
strong
virus-neutralizing
antibody
responses,
especially
following
intranasal
intratracheal
delivery.
Studies
on
reversibility
transmission
further
validated
vaccine’s
stability
non-pathogenicity.
data
indicate
that
QazCovid-live
is
safe,
immunogenic,
prepared
for
clinical
trials,
presenting
potential
strategy
prevention.
Microorganisms,
Journal Year:
2025,
Volume and Issue:
13(4), P. 746 - 746
Published: March 26, 2025
The
implementation
of
COVID-19
policy
and
the
rapid
development
SARS-CoV-2
vaccines
in
early
pandemic
significantly
contained
numerous
outbreaks
reduced
severity
mortality
COVID-19.
However,
population
immunity
induced
by
existing
was
insufficient
to
prevent
outbreaks.
host
wide
spread
Omicron
variants
its
influence
on
emerging
are
attracting
broad
attention.
In
this
study,
a
clinical
data
analysis
patients
indicated
that
pre-vaccination
inflammatory
responses
mitigated
cases
caused
natural
infection
with
BA.5.2.
adaptive
immune
BA.5.2
robust
responses,
including
both
humoral
T
cell-mediated
(IFN-γ)
against
highly
conserved
viral
antigens,
provided
cross-reactive
neutralization
various
variants.
Collectively,
we
report
variants,
which
suggests
live
attenuated
vaccine
desired
safety,
high
efficacy,
spectrum,
long-term
persistence
is
feasible.
Therefore,
suggest
herd
immunity,
achieved
through
vaccination
vaccines,
combined
booster
doses
antiviral
therapy
for
people
loads,
may
contribute
eradication
virus.
ACS Nano,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 9, 2025
Since
the
emergence
of
COVID-19
pandemic,
mRNA
vaccines
have
garnered
significant
attention.
Delivery
systems
affect
effectiveness
vaccines,
yet
there
remains
a
scarcity
vectors
that
can
achieve
safe
and
efficient
delivery
mRNA.
We
took
advantage
self-assembled
glycopeptides
(SAPs)
to
develop
vector
named
Man-MPm,
which
was
coupled
with
mannose
manganese
ions
lymph
node
targeting
STING
pathway
activation.
The
Man-MPm-based
vaccine
exhibited
high
biosafety
across
various
administration
routes,
eliciting
robust
antigen-specific
immune
responses
within
nodes.
Due
elevated
antitumor
immunity,
Man-MPm
significantly
suppressed
tumor
growth
extended
survival
period
mice
in
melanoma
prevention
treatment
models
as
well
colon
cancer
model.
Our
findings
show
addresses
challenges
safety
associated
by
incorporating
node-targeting
ligand
agonist
onto
highly
biocompatible
SAP,
holds
great
potential
for
developing
vaccines.
npj Viruses,
Journal Year:
2024,
Volume and Issue:
2(1)
Published: Aug. 22, 2024
Abstract
Coronaviruses
(CoVs)
have
caused
three
global
outbreaks:
severe
acute
respiratory
syndrome
coronavirus
1
(SARS-CoV-1)
in
2003,
Middle
East
(MERS-CoV)
2012,
and
SARS-CoV-2
2019,
with
significant
mortality
morbidity.
The
impact
of
disease
2019
(COVID-19)
raised
serious
concerns
about
the
preparedness
for
a
pandemic.
Furthermore,
changing
antigenic
landscape
led
to
new
variants
increased
transmissibility
immune
evasion.
Thus,
development
broad-spectrum
vaccines
against
current
future
emerging
CoVs
will
be
an
essential
tool
pandemic
preparedness.
Distinct
phylogenetic
features
within
complicate
limit
process
generating
pan-CoV
vaccine
capable
targeting
entire
Coronaviridae
family.
In
this
review,
we
aim
provide
detailed
overview
CoVs,
their
phylogeny,
various
efforts
developing
vaccines,
future.
Journal of Virology,
Journal Year:
2024,
Volume and Issue:
98(9)
Published: Aug. 29, 2024
Immunocompromised
people
are
at
high
risk
of
prolonged
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
infection
and
progression
to
disease
2019
(COVID-19).
However,
the
efficacy
late-onset
direct-acting
antiviral
(DAA)
therapy
with
therapeutics
in
clinical
use
experimental
drugs
mitigate
persistent
viral
replication
is
unclear.
In
this
study,
we
employed
an
immunocompromised
mouse
model,
which
supports
SARS-CoV-2
explore
treatment
options.
Tandem
immuno-depletion
CD4
Zoonoses,
Journal Year:
2024,
Volume and Issue:
4(1)
Published: Jan. 1, 2024
Objective:
The
global
coronavirus
disease
2019
(COVID-19)
pandemic
was
caused
by
SARS-CoV-2.
authors
developed
an
mRNA
vaccine
(LVRNA009)
that
encoded
the
S
protein
of
Wuhan-Hu-1
strain
and
evaluated
long-term
protection
potential
against
SARS-CoV-2
variants.
Methods:
Mice
were
initially
vaccinated
with
2
doses
LVRNA009,
then
boosted
8
months
later.
virus
neutralization
titers
variants
antigen-specific
T
cell
responses
mice
determined.
These
animals
also
tested
using
viral
challenge
experiments.
Moreover,
a
phase
II
clinical
study
carried
out
in
420
healthy
adults.
Results:
LVRNA009
vaccination
induced
antibodies
protected
from
original
Omicron
BA.1.1
post-boosting.
A
second
booster
dose
further
enhanced
VNTs
Clinical
studies
showed
has
good
safety
immunogenicity
profiles
humans.
Conclusion:
could
provide
confer
better
dose.
findings
indicate
designed
based
on
virus,
might
be
effective
management
COVID-19
pandemic.
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: May 23, 2024
The
immunocompromised
are
at
high
risk
of
prolonged
SARS-CoV-2
infection
and
progression
to
severe
COVID-19.
However,
efficacy
late-onset
direct-acting
antiviral
(DAA)
therapy
with
therapeutics
in
clinical
use
experimental
drugs
mitigate
persistent
viral
replication
is
unclear.
In
this
study,
we
employed
an
mouse
model,
which
supports
explore
treatment
options.
Tandem
immuno-depletion
CD4
